Enliven Therapeutics Financials - Benzinga

Enliven Therapeutics Inc

ELVNNASDAQ

Trade with Public

Trade with Public

$57.40

-0.49-0.85%

Last update: Sep 1, 10:03 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Enliven Therapeutics Financials

Enliven Therapeutics (ELVN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Enliven Therapeutics Q2 EPS $(0.49) Misses $(0.40) Estimate

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.40) by 22.5 percent. This is unchanged from the same period last year.

Benzinga Newsdesk

PRO
Enliven Therapeutics Q1 EPS $(0.38) Beats $(0.46) Estimate

Benzinga Newsdesk

Enliven Therapeutics: Q4 Earnings Insights

Benzinga Insights

PRO
Enliven Therapeutics Q4 EPS $(0.48) Misses $(0.38) Estimate

Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 27.32 percent. This is a 4.35 percent decrease over losses of $(0.46) per share

Benzinga Newsdesk

Dow Jumps Over 250 Points; US Initial Jobless Claims Increase

Avi Kapoor

Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings

Avi Kapoor